These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 33895981)

  • 1. A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials.
    Sinha B; Ghosal S
    Diabetes Ther; 2021 Jun; 12(6):1661-1676. PubMed ID: 33895981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?
    Bejan-Angoulvant T; Cornu C; Archambault P; Tudrej B; Audier P; Brabant Y; Gueyffier F; Boussageon R
    Diabetes Metab; 2015 Jun; 41(3):195-201. PubMed ID: 25958125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2011 Jun; (6):CD008143. PubMed ID: 21678374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
    Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
    Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study.
    van Wijngaarden RPT; Overbeek JA; Heintjes EM; Schubert A; Diels J; Straatman H; Steyerberg EW; Herings RMC
    Diabetes Ther; 2017 Oct; 8(5):1097-1109. PubMed ID: 28921256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study.
    Arnold SV; Khunti K; Tang F; Chen H; Cid-Ruzafa J; Cooper A; Fenici P; Gomes MB; Hammar N; Ji L; Saraiva GL; Medina J; Nicolucci A; Ramirez L; Rathmann W; Shestakova MV; Shimomura I; Surmont F; Vora J; Watada H; Kosiborod M
    Am Heart J; 2022 Jan; 243():232-239. PubMed ID: 34666013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort.
    Gedebjerg A; Almdal TP; Berencsi K; Rungby J; Nielsen JS; Witte DR; Friborg S; Brandslund I; Vaag A; Beck-Nielsen H; Sørensen HT; Thomsen RW
    J Diabetes Complications; 2018 Jan; 32(1):34-40. PubMed ID: 29107454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort.
    Mather KJ; Bebu I; Baker C; Cohen RM; Crandall JP; DeSouza C; Green JB; Kirkman MS; Krause-Steinrauf H; Larkin M; Pettus J; Seaquist ER; Soliman EZ; Schroeder EB; Wexler DJ; Pop-Busui R;
    Diabetes Res Clin Pract; 2020 Jul; 165():108235. PubMed ID: 32450102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
    Poulter NR
    J Hypertens Suppl; 2009 May; 27(1):S3-8. PubMed ID: 19483505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.
    Visser J; Snel M; Van Vliet HA
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003990. PubMed ID: 17054193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: The RODAM study.
    Hayfron-Benjamin C; van den Born BJ; Maitland-van der Zee AH; Amoah AGB; Meeks KAC; Klipstein-Grobusch K; Bahendeka S; Spranger J; Danquah I; Mockenhaupt F; Beune E; Smeeth L; Agyemang C
    J Diabetes Complications; 2019 Aug; 33(8):572-578. PubMed ID: 31167710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.